Pacific Biosciences of California (PACB)
(Delayed Data from NSDQ)
$1.38 USD
+0.02 (1.47%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $1.37 -0.01 (-0.72%) 6:50 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Pacific Biosciences of California (PACB) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$5.65 | $10.00 | $2.50 | 315.44% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for Pacific Biosciences of California comes to $5.65. The forecasts range from a low of $2.50 to a high of $10.00. The average price target represents an increase of 315.44% from the last closing price of $1.36.
Analyst Price Targets (10)
Broker Rating
Pacific Biosciences of California currently has an average brokerage recommendation (ABR) of 2.08 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms. The current ABR compares to an ABR of 1.71 a month ago based on 14 recommendations.
Of the 13 recommendations deriving the current ABR, six are Strong Buy, representing 46.15% of all recommendations. A month ago, Strong Buy represented 64.29%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 8 | 9 | 9 | 9 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 7 | 6 | 5 | 5 | 5 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.08 | 1.86 | 1.71 | 1.71 | 1.71 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/17/2024 | Scotiabank | Sung-Ji Nam | Strong Buy | Strong Buy |
4/16/2024 | Canaccord Genuity | Kyle Mikson | Strong Buy | Strong Buy |
1/3/2024 | Stephens | Mason Carrico | Not Available | Strong Buy |
12/14/2023 | Guggenheim Securities | Subbu Nambi | Not Available | Hold |
11/1/2023 | Cantor Fitzgerald & Co | Ross Osborn | Hold | Strong Buy |
10/17/2023 | Piper Sandler | David M Westenberg | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.08 |
ABR (Last week) | 1.86 |
# of Recs in ABR | 13 |
Average Target Price | $5.65 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 87 of 252 |
Current Quarter EPS Est: | -0.26 |